Previous close | 5.93 |
Open | 5.90 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.90 - 5.97 |
52-week range | 3.04 - 6.17 |
Volume | |
Avg. volume | 6,578 |
Market cap | 106.6M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 0.02 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Execut
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua
MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profileFirst-in-human study in planning with initial data expected in 2025RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement